References


“Civilian Health and Medical Program of the Uniformed Services (CHAMPUS)/TRICARE; Implementation of the Pharmacy Benefits Program,” Federal Register, Vol. 67, No. 71, April 12, 2002.


Hasty, M., J. Schrager, and K. Wrenn, “Physicians’ Perceptions About Managed 
pp. 756–758.

Hoescht, M. R., *Managed Care Digest Series 1999*, Kansas City, Mo.: Hoechst 

223.

Horn, S. D., “The Clinical Practice Improvement (CPI) Model and How It Is Used 
to Examine the Availability of Pharmaceuticals and the Utilization of 
Ambulatory Healthcare Services in HMOs—Results from the Managed Care Outcomes Project (MCOP), *Pharmacoeconomics*, Vol. 10, Suppl. 2, 1996, pp. 50–
55.

Horn, S. D., P. D. Sharkey, and C. Phillips-Harris, “Formulary Limitations and 
the Elderly: Results From the Managed Care Outcomes Project,” *Am J Man 

Horn, S. D., P. D. Sharkey, D. M. Tracy, C. E. Horn, B. James, and F. Goodwin, 
“Intended and Unintended Consequences of HMO Cost-Containment 
Strategies: Results From the Managed Care Outcomes Project,” *Am J Man Care*, 

Kozma, C. M., C. E. Reeder, and E. W. Lingle, “Expanding Medicaid Drug 
Formulary Coverage: Effects on Utilization of Related Services,” *Med Care*, 

Kravitz, R. L., and P. S. Romano, “Managed Care Cost Containment and the Law 
324.

381.

Lederle, F. A., and E. M. Rogers, “Lowering the Cost of Lowering Cholesterol: A 

Long, S., *Regression Models for Categorical and Limited Dependent Variables*, 

Luce, B. R., and R. E. Brown, “The Use of Technology Assessment by Hospitals, 
Health Maintenance Organizations, and Third-Party Payers in the United 

Masia, N. A., “Pharmaceutical Innovation: Lowering the Price of Good Health,” 

McCombs, J. S., and M. B. Nichol, “Pharmacy-Enforced Outpatient Drug 
Treatment Protocols: A Case Study of Medi-Cal Restrictions for Cefaclor,” *Ann 


